Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Solid Biosciences Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDSolid Biosciences Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Solid Biosciences Inc..
If you want to see a demo, head over to the financial segments of AAPL